Remove 2014 Remove FDA Remove Packaging
article thumbnail

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer

pharmaphorum

has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. RxDx Assay – Roche’s immunohistochemistry (IHC) companion diagnostic for identifying ovarian patients eligible for ELAHERE – has been contemporaneously approved by the FDA. ImmunoGen, Inc.

FDA 69
article thumbnail

Securing every dose with an edible security technology for safe medicines

European Pharmaceutical Review

On- or in-dose authentication means that a security measure or anticounterfeit feature is integrated with the dosage form itself, offering product verification and traceability embedded into each medicine, rather than on the secondary package” WHO estimates that >50 percent of the drugs for sale on the internet are fake.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

eMDR System Enhancements

The FDA Law Blog

Manufacturers who submit reports via the FDA Electronic Submissions Gateway are being advised to update their systems by this time. Background FDA first introduced the final rule and guidance on eMDR in 2014 , which we blogged about here. Either way, the information is transmitted to FDA via the ESG. b)(1)(iii).

article thumbnail

MSD secures full approval for Keytruda’s use in MSI-high solid tumours

Pharmaceutical Technology

Broadening uses and secured full approvals Since its first approval in September 2014, Keytruda has achieved blockbuster status on the market. Earlier in March, the FDA shared a draft guidance on how to run clinical trials for the accelerated approval of cancer drugs.

article thumbnail

Guido Rasi steps down, handing the running of EMA to Emer Cooke

pharmaphorum

In his final message as head of the EMA, Rasi said the number of COVID-19 drugs and vaccines being developed by pharma companies is “encouraging,” and pointing to the agency’s pivotal role “in reviewing the available data packages to ensure that our usual high standards of safety, efficacy and quality are achieved and upheld.”.

article thumbnail

Case Study 2 – The Journey Leading to an Approved NDA

Impact Pharmaceutical Services

Over the next year, IMPACT authored the following documents for the client: Pre-NDA meeting package. Subsequent to the on-time submission of the NDA, IMPACT was asked to author the client’s FDA Advisory Committee Briefing Document. 5 clinical study reports. and 2.7.4), and the Clinical Overview (Module 2.5).

article thumbnail

Case Study 2 – The Journey Leading to an Approved NDA

Impact Pharmaceutical Services

Over the next year, IMPACT authored the following documents for the client: Pre-NDA meeting package. Subsequent to the on-time submission of the NDA, IMPACT was asked to author the client’s FDA Advisory Committee Briefing Document. 5 clinical study reports. and 2.7.4), and the Clinical Overview (Module 2.5).